<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004466</url>
  </required_header>
  <id_info>
    <org_study_id>199/13924</org_study_id>
    <secondary_id>R21DK053611</secondary_id>
    <secondary_id>PD-981-183</secondary_id>
    <secondary_id>SPNSG-97.024</secondary_id>
    <nct_id>NCT00004466</nct_id>
  </id_info>
  <brief_title>Pilot Study of Atorvastatin in Children With Chronic Hyperlipidemia Secondary to Nephrotic Syndrome</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Southwest Pediatric Nephrology Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the effect of atorvastatin on the plasma levels of lipids, Lp(a), and&#xD;
      apoproteins for treating hyperlipidemia in children with nephrotic syndrome in whom&#xD;
      proteinuria and hyperlipidemia persist after other appropriate measures to treat their&#xD;
      primary disease have been exhausted.&#xD;
&#xD;
      II. Determine the safety and tolerability of atorvastatin in these patients.&#xD;
&#xD;
      III. Provide preliminary data for a future investigation into the potential effect that&#xD;
      lowering cholesterol levels may have on the rate of progression of renal insufficiency in&#xD;
      such patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE:&#xD;
&#xD;
      This is a randomized, double blind, placebo controlled, multicenter study.&#xD;
&#xD;
      After 3 months of low cholesterol diet, patients are randomized to receive atorvastatin&#xD;
      tablets daily (arm I) or placebo tablets daily (arm II) for 3 months. Arm I patients receive&#xD;
      increasing doses of atorvastatin every 4 weeks until individual maximum tolerated doses&#xD;
      (MTDs) are determined.&#xD;
&#xD;
      After 3 months of treatment, all patients are given atorvastatin in a 6-9 month open label&#xD;
      extended evaluation. Arm I patients receive atorvastatin for an additional 6 months and arm&#xD;
      II patients receive atorvastatin for 9 months with increasing doses of atorvastatin every 4&#xD;
      weeks for the first 3 months until MTDs are determined.&#xD;
&#xD;
      Patients are followed every 6-8 weeks for one year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Very poor enrollment&#xD;
  </why_stopped>
  <start_date type="Actual">October 1998</start_date>
  <completion_date type="Actual">December 1999</completion_date>
  <primary_completion_date type="Actual">December 1999</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in plasma lipid levels</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Nephrotic Syndrome</condition>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <arm_group_label>Atorvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics--&#xD;
&#xD;
        Chronic hyperlipidemia with treatment-resistant nephrotic syndrome; Must have received at&#xD;
        least 2 months of therapy with steroids on a daily or alternate basis&#xD;
&#xD;
        Primary nephropathy described as minimal change nephrotic syndrome, mesangioproliferative&#xD;
        glomerulonephritis, IgM neuropathy, and focal segmental glomerulosclerosis&#xD;
&#xD;
        Glomerular filtration rate at least 30 mL/min&#xD;
&#xD;
        LDL cholesterol at least 160 mg/dL&#xD;
&#xD;
        --Prior/Concurrent Therapy--&#xD;
&#xD;
        No concurrent medications affecting or interacting with lipids or atorvastatin, with the&#xD;
        exception of angiotensin converting enzyme inhibitors at discretion of referring physician,&#xD;
        including: lipid-lowering medications, beta blockers, thiazides, fish oils, cyclosporine,&#xD;
        Cytoxan, azathioprine, chlorambucil, and erythromycin&#xD;
&#xD;
        Concurrent prednisone and other corticosteroids allowed on a continual basis at a dose of&#xD;
        no greater than 1 mg/kg every other day (maximum dose, no greater than 40 mg every other&#xD;
        day); Concurrent acute courses of steroids no greater than 1 week for other unrelated&#xD;
        conditions (e.g., asthma) also allowed&#xD;
&#xD;
        --Patient Characteristics--&#xD;
&#xD;
        Hepatic: ALT or AST less than 2 times normal&#xD;
&#xD;
        Renal: See Disease Characteristics; Creatine phosphokinase less than 3 times normal&#xD;
&#xD;
        Other: No history of familial hypercholesterolemia; No systemic disease such as systemic&#xD;
        lupus, Schoenlein-Henoch purpura, Hodgkin's disease, polyarteritis nodosum, sickle cell&#xD;
        disease, or HIV; Not pregnant; Effective contraception required of all adolescent patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Hogg</last_name>
    <role>Study Chair</role>
    <affiliation>Southwest Pediatric Nephrology Study Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical City Dallas Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>October 18, 1999</study_first_submitted>
  <study_first_submitted_qc>October 18, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 1999</study_first_posted>
  <last_update_submitted>September 14, 2017</last_update_submitted>
  <last_update_submitted_qc>September 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cardiovascular and respiratory diseases</keyword>
  <keyword>hyperlipidemia</keyword>
  <keyword>nephrotic syndrome</keyword>
  <keyword>rare disease</keyword>
  <keyword>renal and genitourinary disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephrotic Syndrome</mesh_term>
    <mesh_term>Nephrosis</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

